Delivery Order SPE2DR25D1017-SPE2DR26F9ADN
- Not listed
- The Defense Logistics Agency awarded a $1,309.59 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials on September 25, 2025, with completion expected by September 26, 2025. This competitive award utilizes a firm fixed price contract type with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies...
- The Defense Logistics Agency awarded a delivery order valued at $5,320.12 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit dose 3 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of December 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and pharmaceutical distribution operations. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,668.19 to AmerisourceBergen Drug Corp for Yupelri 175 micrograms per 3 milliliters solution in unit dose vials. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed at the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,670.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL Solution in unit dose vials. The order, issued on August 18, 2025, with completion targeted for August 19, 2025, represents a pharmaceutical supply delivery supporting federal medical procurement needs. This delivery order is classified as a child contract under AmerisourceBergen's broader federal contracting relationship and involves no set-aside...
- The Defense Logistics Agency awarded a $1,973.31 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 1, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,985.04 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials. This competitively awarded, firm fixed price delivery order was issued on May 23, 2025, with an ultimate completion date of May 27, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. No set-aside designation was applied to this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,528.21 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose vials. This firm fixed price delivery order was competitively awarded without a set-aside designation and is scheduled for completion on August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award represents a...
- This delivery order, valued at $23,434.10 with a firm fixed price, was awarded on December 10, 2025, to AmerisourceBergen Drug Corp for the supply of Yupelri 175 mcg/3 ml solution in unit dose 3 ml vials. The contract is non-set-aside and competitively awarded, with performance to be completed by December 11, 2025, at the company's facility in Conshohocken, Pennsylvania. The Defense Logistics Agency, which operates under the Department of Defense, is the funding federal agency for this...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $2,261.31 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide YUPELRI 175 MCG/3 ML SOLUTION UD 3ML. This delivery order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $32,599.85 contract is for the supply of YUPELRI 175 MCG/3 ML SOLUTION UD 3ML, a specialty pharmaceutical product. The delivery order has a performance period through March 14, 2024. Amerisourcebergen Drug Corp serves as a prime contractor for DLA, providing a wide...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9ADNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,226.87 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit dose 3 ml vials. This is a firm fixed price delivery order with no set-aside designation, competitively awarded on November 24, 2025, with an ultimate completion date of November 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor supplying a comprehensive range of medications and medical supplies to support military and federal healthcare systems globally. The company's contract portfolio with the Defense Logistics Agency demonstrates its role as a critical vendor for federal medical procurement, with delivery orders covering various therapeutic domains including specialty medications, generic and brand-name drugs, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 11/23/25 |